Simon Read Sells 2,777 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock

Key Points

• Director Simon Read sold 2,777 Dianthus Therapeutics shares at an average price of $109.55, generating $304,220 and reducing his ownership by 50%.
• DNTH shares fell 3.0% to $108.49 after the company reported a quarterly loss of $0.90 per share, missing estimates, despite revenue exceeding expectations.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $124.27; institutional investors own 47.53% of the stock.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) Director Simon Read sold 2,777 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $109.55, for a total transaction of $304,220.35. Following the transaction, the director owned 2,777 shares of the company's stock, valued at $304,220.35. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Dianthus Therapeutics Stock Down 3.0%

Shares of DNTH stock traded down $3.31 on Tuesday, reaching $108.49. The company's stock had a trading volume of 777,875 shares, compared to its average volume of 972,407. The company has a market capitalization of $5.93 billion, a P/E ratio of -26.14 and a beta of 1.22. Dianthus Therapeutics, Inc. has a 12-month low of $19.00 and a 12-month high of $114.55. The stock's 50 day simple moving average is $95.17 and its 200-day simple moving average is $81.36.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The business had revenue of $0.76 million for the quarter, compared to analysts' expectations of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. Research analysts expect that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

Large investors have recently bought and sold shares of the stock. Raymond James Financial Inc. bought a new stake in Dianthus Therapeutics in the second quarter valued at approximately $27,000. First Horizon Corp bought a new position in shares of Dianthus Therapeutics in the first quarter worth approximately $32,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Dianthus Therapeutics in the fourth quarter worth $40,000. Russell Investments Group Ltd. purchased a new position in shares of Dianthus Therapeutics in the third quarter worth $64,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company's stock worth $80,000 after buying an additional 3,317 shares during the period. 47.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on DNTH. Raymond James Financial reiterated a "strong-buy" rating and set a $131.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th. Weiss Ratings restated a "sell (d-)" rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Wedbush lifted their price objective on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an "outperform" rating in a report on Wednesday, August 5th. TD Cowen reiterated a "buy" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Wolfe Research reissued an "outperform" rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Dianthus Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $124.27.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source